Basic Medical Theory Research

[1] Rossella M,Laura M,Francesca O,et al.Comparison Betwe en Soluble ST2 and High-Sensitivity Troponin I in Predicting Short-Term Mortality for Patients Presenting to the Emerge ncy Department With Chest Pain[J].Annals of Laboratory Medi cine,2017,37(2):137.
[2] Zhang Y,Fan Z, Liu H ,et al.Correlation of plasma soluble suppression of tumorigenicity-2 level with the severity and stability of coronary atherosclerosis[J].Coronary Artery Dis ease,2020.
[3] Park S,Kim I C,Kim H ,et al.Ability of soluble ST2 to predict left ventricular remodeling in patients with acute coronary syndrome[J].Heart and Vessels,2021.
[4] Seki K, Sanada S, Kudinova AY, Steinhauser ML, Handa V, Gannon J,Lee RT.Interleukin-33 prevents apoptosis and impro ves survival after experimental myocardial infarction through ST2 signaling[J].Circ Heart Fail.2009,2,684-691.
[5] Kokkoz Ç, Bilge A, Irik M, Dayangaç HI, Hayran M, Akarca FK, Erdem NB, Çavuş M. Prognostic value of plasma ST2 in patients with non-ST segment elevation acute coronary syndrome.Turk J Emerg Med.2018 Feb9;18(2):62-66.
[6] Kohli P,Bonaca MP, Kakkar R,et al.Role of ST2 in nonST-elevation acutecoronary syndrome in the MERLIN-TIMI 36 trial.Clin Chem,2012,58(1):257-266.
[7] Demyanets S, Speidl WS, Tentzeris I, Jarai R, Katsaros KM, Farhan S, etal. Soluble ST2 and interleukin-33 levels in coronary artery disease: relation to disease activity and adverse outcome.PLoS One 2014;9:e95055.
[8] Li Y,Han C,Zhang P,et al. Association between serum S100A1 level and global registry of acute coronary events score in patients with non-ST-segment elevati on acute coronary syndrome[J]. J Int Med Res,2018,46(7):2670-2678.
[9] Shimpo M, Morrow D A, Weinberg E O, et al. Serum levels of the interleukin-1receptor family member ST2 predict mortality and clinical outcome in acute myocardiaml infarct ion[J]. Circulation,2004,109(18):2186-2190.
[10] Engelbertsen D, Andersson L, Ljungcrantz I, Wigren M,Hedblad B, Nilsson J, Björkbacka H. T-helper 2 immunity is associated with reduced risk of myocardial infarction and stroke. Arterioscler Thromb Vasc Biol.2013 Mar;33(3):637-44.
[11] P,Kohli,M,et al.Role of ST2 in Non-ST-Elevation Acu te Coronary Syndrome in the MERLIN-TIMI 36 Trial[J].Clinical Chemistry,2011,58(1).
[12] Weir R A , Miller A M , Murphy G .Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction.[J].Journal of the American College of Cardiology,2010,55(3).
[13] 孙爱梅,刘婷,陈还珍.可溶性ST2对冠心病的危险分层价值及其与心功能的关系[J].中国心血管杂志,2017,22(1):19-23.
[14] Schmitz J,Owyang A,Oldham E,et al.IL-33,an interleuk in-1-likecytokine that signals via the IL-1 receptor-relat ed protein ST2 andinduces T helper type 2-associated cytoki nes[J].Immunity,2005,23(5):479-490.
[15] Weinberg E O,Shimpo M,De Keulenaer G W, et al.Expre ssion and Regulation of ST2, an Interleukin-1 Receptor Family Member, in Cardiomyocytes and Myocardial Infarction [J].Circulation,2003,106(23):2961-2966.
[16] Benoit J L,Hicks C W,Engineer R S,et al.ST2 in Emerge ncy Department Patients With Noncardiac Dyspnea[J].Academic Emergency Medicine,2013,20(11).
[17] Palmer G,Talabot-Ayer D,Céline Lamacchia,et al.Inhib ition of interleukin-33 signaling attenuates the severity of experimental arthritis.[J].Arthritis & Rheumatology, 2014,60(3):738-749.
[18] A C I T , B S K , A D M R ,et al.Sensitivity and binding kinetics of an ultra-sensitive chemiluminescent enzyme-lin ked immunosorbent assay at arrays of antibodies[J].Journal of Immunological Methods,2019,474:112643.